UNSPSC 51283422: Fumoxicillin

This classification denotes a penicillin antibiotic with the molecular formula C21H21N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C7H9M9492J, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((((2-furanylmethylene)amino)(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, (2s-(2alpha,5alpha,6beta(s*)))- but more generally known as fumoxicillin, which bears US NIH Compound Identifier 72000.

UNSPSC 51283422 Fumoxicillin is a Commodity code that nominally covers a specific antibiotic pharmaceutical, yet the recent state and local opportunities tagged under it show little relevant activity — the sourced solicitations address naloxone (opioid reversal), first aid supplies, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs, none of which align with fumoxicillin procurement. The code does not appear to see regular state and local buying activity that matches its defined scope, suggesting either sparse demand for this particular drug or a tagging mismatch in the opportunities that cite it.

The geographic and issuing-body spread of the four recent opportunities reflects scattered state and local procurement: Seminole County (Florida) seeking naloxone and drug deactivation systems, the City of Tampa (Florida) bidding medical and first aid supplies for its fire department, the Texas Health and Human Services Commission pursuing direct-to-manufacturer pharmacy program capacity, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administering a multi-state generic pharmaceutical RFP with participating agencies in Minnesota and Oregon. Beyond the clear mismatch between the code name and the actual solicitations, the issuing bodies span county health departments, municipal fire operations, state HHS commissions, and cooperative purchasing vehicles — a mix typical of pharmaceutical and medical supply procurement at the state and local level. No recent opportunities directly soliciting fumoxicillin or closely related pharmaceutical products appear in the available records.